Zeneca and UK Imperial Cancer Research Fund (ICRF) collaborate on cancer diagnostics
This article was originally published in Clinica
Zeneca and the UK Imperial Cancer Research Fund (ICRF) have formed a partnership to develop DNA diagnostics for cancer. A joint committee will pick commercial prospects from targets identified by ICRF. Both organisations will be involved in early development. Clinical evaluation will be conducted by the ICRF and Zeneca will commercialise successful tests. The deal will provide ICRF with £1.2 million ($1.8 million) in research funding plus royalties on sales of diagnostic products.